Oğuzhan Yaralı

Oğuzhan Yaralı

Auto-generated profile, based on publicly available information

Oğuzhan Yaralı

Erzurum Regional Training and Research Hospital

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Hormone Research in Paediatrics
Verified
Journal Article
Closed access
PDF file
EKErdal Kurnaz
Erdal Kurnaz
EBEmine Kartal Baykan
Emine Kartal Baykan
ATAyberk Türkyılmaz
Ayberk Türkyılmaz
OYOğuzhan Yaralı
Oğuzhan Yaralı
ZAZehra Yavaş Abalı
Zehra Yavaş Abalı
TGTulay Guran
Tulay Guran
Context: Steroid 17α-hydroxylase/17,20-lyase deficiency (17OHD) is characterized by decreased sex steroids and cortisol, and excessive mineralocorticoid action. The clinical symptoms of hypocortisolemia are subtle. Aim: The clinical, biochemical, and molecular characteristics of patients with 17OHD were evaluated to determine the factors influencing the time of diagnosis and the management. Patients and Methods: Clinical data, steroid profiles by liquid chromatography-tandem mass spectrometry, and Sanger sequencing of the CYP17A1 gene was evaluated in 12 patients with 17OHD diagnosed between 2004 and 2020. Results: Median age of diagnosis was 13.9 (range: 0.04–29.5) years. Ten of 12 patients had 46,XY karyotype. Except for one boy with partial 17OHD, all patients had female external genitalia hence raised as females. The clinical presentation of 17OHD was earlier (median age: 7 years) in patients, who presented with severe hypertension, atypical genitalia, or positive family history (n = 6, 50%) than those without (median age: 15.3 years; p = 0.0005). The latter group presented with amenorrhea (n = 6, 50%). Steroid profile of patients uniformly showed a typical pattern of 17OHD regardless of the age at diagnosis. Serum gonadotropin concentrations were elevated in patients >12 years (n = 7), normal in pre-adolescents (n = 4), and low in a patient, who had a digenic inheritance of homozygous CYP17A1 and KISS1R mutations. Conclusions: Early clinical presentation and diagnosis in 17OHD are associated with symptomatic hypertension in both 46,XX and 46,XY patients or inadequate virilization of external genitalia in 46,XY partial 17OHD. In the absence of these, the clinical presentation is at late pubertal ages at which time amenorrhea and elevated gonadotropins are the hints for diagnosis.

30 October 2015 in Medical Principles and Practice
Verified
Journal Article
Open access
PDF file
AOAdalet Ozcicek
Adalet Ozcicek
NCNihal Cetin
Nihal Cetin
FCFerda Keskin Cimen
Ferda Keskin Cimen
LTLevent Tumkaya
Levent Tumkaya
IMIsmail Malkoc
Ismail Malkoc
BSBahadir Suleyman
Bahadir Suleyman
Objective: The aim of this study was to assess the impact of resveratrol (RST) on oxidative stress induced by methotrexate in rat ileum tissue. Materials and Methods: Twenty-four rats were divided into 4 groups with 6 in each group. Each rat was orally administered the following every day for 30 days: group 1 (MTXG), methotrexate (MTX; 5 mg/kg); group 2 (RMTXG), MTX (5 mg/kg) plus RST (25 mg/kg/day); group 3 (RSTG), RST alone (25 mg/kg/day), and group 4 (controls), distilled water. After the rats had been sacrified, the ilea were removed for the assessment of malondialdehyde (MDA), total glutathione (tGSH) and glutathione peroxidase (GSH-Px). Gene expression analyses for interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α) and myeloperoxidase (MPO) were also performed. Hematoxylin and eosin-stained paraffin-embedded sections of the ileum were analyzed under a light microscope and the findings were recorded. Statistical analyses of the data were performed using one-way ANOVA. Results: The administration of MTX in group 1 yielded a higher level of MDA (8.33 ± 2.5 μmol/g protein, p < 0.001) and lower levels of tGSH (0.97 ± 0.29 nmol/g protein) and GSH-Px (5.22 ± 0.35 U/g protein, p < 0.001) compared to the other groups. MTX also increased IL-1β (40.33 ± 5.43 gene expression levels), TNF-α (6.08 ± 0.59) and MPO gene expression (9 ± 1.41) in group 1 compared to the controls (11.33 ± 2.07, 2.15 ± 0.33 and 3.43 ± 0.48, respectively, p < 0.001). The impact of RST on IL-1β, TNF-α and MPO gene expression induced by MTX was observed as a reversal of these findings (p < 0.05). Severe inflammation, damage to the villus epithelium and crypt necrosis was observed histopathologically in the MTXG group, whereas only mild inflammation was seen in the RMTXG group. Conclusion: In this study, ileal damage caused by MTX was inhibited by RST.

22 February 2022 in Molecular Syndromology
Verified
Journal Article
Open access
PDF file
ATAyberk Türkyılmaz
Ayberk Türkyılmaz
ETEmine Tekin
Emine Tekin
OYOğuzhan Yaralı
Oğuzhan Yaralı
AÇAlper Han Çebi
Alper Han Çebi
Introduction: The α subunit of voltage-gated sodium channels in mammals is encoded by 9 different genes, and variations in the SCN1A, SCN2A, SCN3A, and SCN8A genes highly expressed in the CNS have been associated with epilepsy phenotypes. This study aimed at investigating the frequency of SCN1A gene variations in Dravet syndrome (DS) and GEFS+ spectrum phenotype cases and discussing the molecular results in the context of genotype-phenotype correlation. Methods: Fifteen patients diagnosed with DS and 54 patients meeting the GEFS+ spectrum criteria were included in this study. All patients were evaluated by next-generation sequencing and multiplex ligation-dependent probe amplification using an SCN1A gene commercial kit. Results: A total of 17 different variants were detected in 18 index cases (26%), of which 7 were novel variations (p.M1R, p.M147T, p.I767L, p.N1391Ifs*5, p.R1886G, p.E1915G, p.R1933Q). Of the 18 cases with variation in the SCN1A gene, 12 had DS and 6 had GEFS+ phenotype. The variations were de novo in all DS cases and in 1 case with a GEFS+ phenotype; in 5 GEFS+ cases, the variant was inherited from the affected parent. Discussion: This study contributes to the variation spectrum in cases with DS and GEFS+ phenotype with the novel variants detected. SCN1A genetic analysis can help in determining whether antiseizure medication should be selected or avoided in cases with variations. The elucidation of the molecular etiology makes it possible to provide the family with effective genetic counseling for future pregnancies.

31 August 2019 in Kırıkkale Üniversitesi Tıp Fakültesi Dergisi
Verified
Journal Article
Closed access
MBMuharrem Bayrak
Muharrem Bayrak
KÇKenan ÇADIRCI
Kenan ÇADIRCI
OYOğuzhan Yarali
Oğuzhan Yarali
Amaç: Ailesel Akdeniz ateşi otozomal resesif geçen ve MEFV genindeki mutasyonların yol açtığı genetik bir hastalıktır. Bölgemizde sık görülen genetik bir hastalık olması ve mutasyonlarla ilgili epidemiyolojik verilerin az olması nedeniyle ailesel Akdeniz ateşi vakalarında, MEFV mutasyonlarının tiplerinin ve sıklığının belirlenmesi amaçlandı.Gereç ve Yöntemler: Çalışmaya 212 MEFV mutasyonu saptanmış hasta dâhil edildi. Hastaların verileri retrospektif olarak tarandı. MEFV mutasyon analizi Next Generation Sequence yöntemi ile yapıldı.Bulgular: Çalışma hastalarının 116 (%54.71)’ı kadın ve 96 (%45.29)’ı erkekti. En sık saptanan MEFV mutasyonu M694V (%34.9) idi. E148Q (%26), V726A (%16) ve M68OI (%8.3) diğer sık saptanan mutasyon tipleriydi. MEFV mutasyonu saptanan hastaların cinsiyetlere göre dağılımları incelendiğinde; erkeklerde M694V, E148Q, V726A, M68OI ve R761H mutasyonları, kadınlarda ise M694V, E148Q, V726A, M68OI ve P369S mutasyonlarının daha sık olduğu izlendi.Sonuç: MEFV mutasyon tiplerinin sıklığını belirlemek amacıyla yapılan çalışmamızda ailevi Akdeniz ateşi hastalığının bazı bölgelerde yüksek oranda gözlendiği ve bu farklı oranların toplumlar arasında farklılıklara yol açabileceği gösterilmiştir. MEFV mutasyon tiplerinin sıklığının bölgeden bölgeye ve popülasyondan popülasyona değişebileceğini düşünüyoruz. Bu nedenle, değişen nüfus ve komşu ülkelerin istikrarsızlığı nedeniyle, bölgemizde ve ülkemizde MEFV mutasyon tiplerinin sıklığını belirlemeye yönelik geniş nüfus temelli çalışmalar yapılmalıdır.

25 October 2024 in Scandinavian Journal of Clinical and Laboratory Investigation
Verified
Journal Article
Closed access
OYOğuzhan Yaralı
Oğuzhan Yaralı
SASezai Arslan
Sezai Arslan
ÖÖÖzge Beyza Gündoğdu Öğütlü
Özge Beyza Gündoğdu Öğütlü
MGMustafa Can Guler
Mustafa Can Guler
BABüşra Nur Akgül
Büşra Nur Akgül
ABTRACTThis study retrospectively reviews individuals diagnosed with biotinidase deficiency in Eastern Anatolia to analyze the genetic variants and their relationship with biotinidase activity levels. The research focuses on determining the percentage impact of different variants on enzyme activity. The study included 357 patients who presented to Erzurum City Hospital with symptoms of biotinidase deficiency between 2018 and 2023 and were referred to the medical genetics department. Biotinidase enzyme levels were determined using spectrophotometric and colorimetric techniques, while Sanger sequencing analyzed the four exons and intron boundaries of the BTD gene. In the analysis of 357 patients (181 boys, 176 girls), the most frequent variant was c.1270G > C | p.Asp424His. Biotinidase enzyme activity was above 30% in 97.3% of patients with a homozygous p.D424His mutation. The mutations that caused the most significant decrease in enzyme activity were c.410G > A p.Arg137His, c.38_delinsTCC p.Cys13phefs*36, and c.1535C > T p.Thr512Met. Hearing loss (4 patients) and optic atrophy (1 patient) were mainly observed in patients with the c.38_delinsTCC mutation (homozygous or heterozygous). Most patients were asymptomatic, and mild symptoms were effectively prevented with biotin treatment. This study provides a detailed analysis of genetic diversity and clinical presentation in biotinidase deficiency cases in Eastern Anatolia, demonstrating the efficacy of biotin treatment. It highlights the significant role of genetic variants in phenotypic diversity and the need for personalized treatment, calling for further genetic research to enhance understanding of variant diversity and its impact on enzyme activity.

8 October 2024 in Hormone Research in Paediatrics
Verified
Journal Article
Open access
EKErdal Kurnaz
Erdal Kurnaz
ATAyberk Türkyılmaz
Ayberk Türkyılmaz
OYOğuzhan Yaralı
Oğuzhan Yaralı
ADAyşe Sena Dönmez
Ayşe Sena Dönmez
ACAtilla Cayir
Atilla Cayir
Introduction: Pathogenic variants in the genes involved in the formation of thyroid tissue and thyroid hormone secretion have been reported to cause congenital hypothyroidism (CH) in some cases. This study aimed to evaluate the clinical and genetic findings of CH cases thought to be due to genetic variants. Methods: The study included cases whose genetic analysis was performed in accordance with the Congenital Hypothyroidism: A 2020–2021 Consensus Guidelines Update Guidelines recommendations criteria and analyzed them using the next-generation sequencing panel. Results: Sixty one Turkish patients from 45 families were included in the study. The overall frequency of variant detection was 37.7% (out of 45 families, 17 had a positive mutation). Segregation was carried out for all families with positive variants. Variants in the TPO gene are the most frequently encountered, and this situation was identified in 10 families. Variants followed this in the TSHR gene in 7 families, variants in the DUOX2 gene in 5 families, and two variants in the TG and NKX2-1 genes in 2 families each, which are six novel variants. Furthermore, among the NKX2-1 cases, one had thyroid involvement only, while the other had chorea only. We did not find differences between cases with detected mutations and mutation-negative cases regarding gender, neonatal/perinatal parameters, initial thyroid function values, and thyroid morphology. Conclusion: In the current investigation, rare new variations in genes known to be related to CH were discovered, adding to the molecular genetic spectrum. When we compare the overall variant detection frequency, the selection criterion for genetic analysis based on the current guidelines is quite rational, considering the benefits and costs, on the other hand, present in new genes awaiting discovery. Also, TSHR mutations are likely to be common and may account for more than 5% of thyroid dysgenesis cases if we include nonfamilial thyroid dysgenesis.